Park, Jin-Sun; Shin, Joon-Han; Hong, Taek-Jong; Seo, Hong-Seog; Shim, Wan-Joo; Baek, Sang-Hong; Jeong, Jin-Ok; Ahn, Youngkeun; Kang, Woong-Chol; Kim, Young-Hak; Kim, Sang-Hyun; Hyon, Min-Su; Choi, Dong-Hoon; Nam, Chang-Wook; Park, Tae-Ho; Lee, Sang-Chol; Kim, Hyo-Soo
Drug design, development and therapy
2016NA ; 10 ( 1 ) :2599-609.
PMID : 27574399
ÀúÀÚ »ó¼¼Á¤º¸
Park, Jin-Sun -
Shin, Joon-Han -
Hong, Taek-Jong -
Seo, Hong-Seog -
Shim, Wan-Joo -
Baek, Sang-Hong -
Jeong, Jin-Ok -
Ahn, Youngkeun -
Kang, Woong-Chol -
Kim, Young-Hak -
Kim, Sang-Hyun -
Hyon, Min-Su -
Choi, Dong-Hoon -
Nam, Chang-Wook -
Park, Tae-Ho -
Lee, Sang-Chol -
Kim, Hyo-Soo -
ABSTRACT
The pill burden of patients with hypertension and dyslipidemia can result in poor medication compliance. This study aimed to evaluate the efficacy and safety of fixed-dose combination (FDC) therapy with olmesartan medoxomil (40 mg) and rosuvastatin (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. This multicenter, randomized, double-blind, factorial-design study included patients aged ??0 years with mild to moderate essential hypertension and dyslipidemia. Patients were randomly assigned to receive FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin), 40 mg olmesartan medoxomil, 20 mg rosuvastatin, or a placebo. The percentage change from baseline in low-density lipoprotein cholesterol levels was compared between FDC therapy and olmesartan medoxomil, and the change from baseline in diastolic blood pressure was compared between FDC therapy and rosuvastatin 8 weeks after treatment. A total of 162 patients were included. The least square mean percentage change (standard error) from baseline in low-density lipoprotein cholesterol levels 8 weeks after treatment was significantly greater in the FDC than in the olmesartan medoxomil group (-52.3% [2.8%] vs -0.6% [3.5%], P<0.0001), and the difference was -51.7% (4.1%) (95% confidence interval: -59.8% to -43.6%). The least square mean change (standard error) from baseline in diastolic blood pressure 8 weeks after treatment was significantly greater in the FDC group than in the rosuvastatin group (-10.4 [1.2] mmHg vs 0.1 [1.6] mmHg, P<0.0001), and the difference was -10.5 (1.8) mmHg (95% confidence interval: -14.1 to -6.9 mmHg). There were 50 adverse events in 41 patients (22.7%) and eight adverse drug reactions in five patients (2.8%). The study found that FDC therapy with olmesartan medoxomil and rosuvastatin is an effective, safe treatment for patients with hypertension and dyslipidemia. This combination may improve medication compliance in patients with a large pill burden.
dyslipidemia; fixed-dose combination therapy; hypertension; olmesartan medoxomil; rosuvastatin
MESH
Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use, Double-Blind Method, Drug Combinations, Dyslipidemias/*drug therapy, Female, Humans, Hypertension/*drug therapy, Male, Middle Aged, Olmesartan Medoxomil/administration & dosage/adverse effects/*therapeutic use, Republic of Korea, Rosuvastatin Calcium/administration & dosage/adverse effects/*therapeutic use
¸µÅ©